LDL Target After Myocardial Infarction

Primary LDL-C Goals

The American College of Cardiology recommends LDL-C <55 mg/dL (<1.4 mmol/L) with ≥50% reduction from baseline for patients with established coronary heart disease, who are classified as "very high risk" 1, 2
The European Society of Cardiology guidelines recommend LDL-C <1.8 mmol/L (~70 mg/dL) OR a ≥50% reduction if baseline LDL-C is between 1.8-3.5 mmol/L (70-135 mg/dL) 3
The American College of Cardiology and American Heart Association guidelines recommend LDL-C <70 mg/dL as a reasonable option for very high-risk patients 4, 5, 6, 7

The European Society of Cardiology recommends starting high-intensity statin therapy as early as possible during hospitalization and maintaining long-term 3
High-intensity statins are defined as atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily 3, 2
If LDL-C remains >55 mg/dL on maximally tolerated statin, add ezetimibe 10 mg daily 2
If LDL-C still >55 mg/dL despite statin plus ezetimibe, add a PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) 2

If triglycerides are ≥200 mg/dL, the non-HDL-C target should be <85 mg/dL (<2.2 mmol/L) for very high-risk patients 1, 2
Non-HDL-C is calculated as total cholesterol minus HDL-C 4, 5

Every 1.0 mmol/L (approximately 39 mg/dL) reduction in LDL-C is associated with a 20-25% reduction in cardiovascular mortality and non-fatal myocardial infarction 1
The PROVE-IT TIMI 22 trial demonstrated that achieving median LDL-C of 62 mg/dL with atorvastatin 80 mg resulted in 16% reduction in major cardiovascular events compared to achieving 95 mg/dL with pravastatin 40 mg 4, 5, 7, 2
Clinical trials have shown continuous cardiovascular benefit with no lower threshold—patients achieving LDL-C <25 mg/dL demonstrate ongoing risk reduction without safety concerns 2

There is no evidence of harm from achieving very low LDL-C levels 2
Genetic conditions with lifelong very low LDL-C demonstrate no adverse effects and reduced cardiovascular risk 2

Most patients require high-intensity statins, not moderate-intensity 3
Do not hesitate to add ezetimibe and PCSK9 inhibitors when targets are not met 2
Guidelines explicitly recommend against de-escalating treatment when low LDL-C levels are achieved and therapy is well-tolerated 8
Lipid-lowering medications should be initiated before hospital discharge 6, 2
Regular monitoring of LDL-C levels is needed to ensure sustained response to therapy 8